Action Callisto - KAL

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Callisto Pharmaceuticals, Inc. Receives Notice of Delisting From Amex - Subject to Appeal -

Callisto Pharmaceuticals, Inc. (AMEX: KAL), announced today that on April 7, 2008, it received notice from the American Stock...

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

NEW YORK, Sept. 20 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the...

American Stock Exchange Accepts Callisto Pharamceuticals' Plan of Compliance and Extension to Regain Compliance with Standards

NEW YORK, Aug. 29 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the...

Hagens Berman Sobol Shapiro: Class Action Lawsuit Filed Against Korean Air Lines

Plaintiff claims suffered damages in Korean Air Lines price fixing conspiracy SEATTLE, Aug. 10 /PRNewswire/ -- Seattle-based law firm Hagens...

Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight...

Callisto Reports on Second-Quarter 2007 Milestones

Company Cites Continuing Progress on Clinical and Preclinical Programs NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc...

Callisto Pharmaceuticals Raises $11.2 Million in Series B Preferred Stock Financing

NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company primarily focused...

Callisto Pharmaceuticals Opens Additional Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

NEW YORK, June 25 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the...

Callisto Pharmaceuticals, Inc. Receives Notice From AMEX

NEW YORK, June 22 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (AMEX:KAL), a biopharmaceutical company primarily focused on the...

Callisto Pharmaceuticals Files Suit Against Former Executive Vice President for Breach of Employment Agreement, Fraud, Conversio

NEW YORK, June 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company focused on the...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

KAL - Frequently Asked Questions (FAQ)

What is the current Callisto share price?

The current share price of Callisto is US$ 0,00

What is the 1 year trading range for Callisto share price?

Callisto has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MSTZT Rex 2X Inverse MSTR Daily Target ETF	US$ 28,05 (23,57%)	19,9M
MWGMulti Ways Holdings Limited	US$ 0,324 (19,12%)	248,72k
CTMCastellum Inc	US$ 0,916 (17,44%)	2,69M
ETHDProshares Ultrashort Ether ETF	US$ 35,15 (17,40%)	276,13k
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 3,845 (17,05%)	77,88M
ATCHAtlasClear Holdings Inc	US$ 4,00 (-28,06%)	2,54M
MSTUT Rex 2X Long MSTR Daily Target ETF	US$ 4,83 (-23,33%)	71,78M
ETHTProshares Ultra Ether ETF	US$ 9,54 (-17,40%)	2,71M
ETUT Rex 2X Long Ether Daily Target ETF	US$ 17,59 (-17,18%)	42,17k
TSLTT Rex 2X Long Tesla Daily Target ETF	US$ 19,67 (-17,07%)	6,45M
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 3,845 (17,05%)	77,88M
MSTUT Rex 2X Long MSTR Daily Target ETF	US$ 4,83 (-23,33%)	71,78M
SPXSDirexion Daily S&P 500 Bear 3X Shares New	US$ 6,0599 (0,66%)	70,31M
ETHU2x Ether ETF	US$ 3,485 (-16,83%)	64,35M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF	US$ 3,005 (2,04%)	62,37M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Callisto Pharmaceuticals, (KAL)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

KAL Dernières nouvelles

Callisto Pharmaceuticals, Inc. Receives Notice of Delisting From Amex - Subject to Appeal -

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

American Stock Exchange Accepts Callisto Pharamceuticals' Plan of Compliance and Extension to Regain Compliance with Standards

Hagens Berman Sobol Shapiro: Class Action Lawsuit Filed Against Korean Air Lines

Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

Callisto Reports on Second-Quarter 2007 Milestones

Callisto Pharmaceuticals Raises $11.2 Million in Series B Preferred Stock Financing

Callisto Pharmaceuticals Opens Additional Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

Callisto Pharmaceuticals, Inc. Receives Notice From AMEX

Callisto Pharmaceuticals Files Suit Against Former Executive Vice President for Breach of Employment Agreement, Fraud, Conversio

KAL - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Callisto Pharmaceuticals, (KAL) Cours

Callisto Pharmaceuticals, (KAL)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

KAL Dernières nouvelles

Callisto Pharmaceuticals, Inc. Receives Notice of Delisting From Amex - Subject to Appeal -

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

American Stock Exchange Accepts Callisto Pharamceuticals' Plan of Compliance and Extension to Regain Compliance with Standards

Hagens Berman Sobol Shapiro: Class Action Lawsuit Filed Against Korean Air Lines

Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

Callisto Reports on Second-Quarter 2007 Milestones

Callisto Pharmaceuticals Raises $11.2 Million in Series B Preferred Stock Financing

Callisto Pharmaceuticals Opens Additional Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

Callisto Pharmaceuticals, Inc. Receives Notice From AMEX

Callisto Pharmaceuticals Files Suit Against Former Executive Vice President for Breach of Employment Agreement, Fraud, Conversio

KAL - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE